The EHMT2 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma epithelial cells with targeted disruption of the EHMT2 gene. This gene-edited pool, derived from the widely used A-549 cell line, offers a loss-of-function model for studying EHMT2-dependent epigenetic regulation without clonal isolation, preserving heterogeneous genetic backgrounds relevant to bulk functional assays. The polyclonal format is suitable for researchers requiring a representative knockout population for screening and comparative studies.
The parental A-549 cell line was originally established from a 58-year-old Caucasian male with lung adenocarcinoma and is extensively employed as a model of human alveolar type II epithelium. These cells are a cornerstone in respiratory research, particularly for investigating lung cancer biology, drug response, and epithelial cell function. Their robust growth characteristics and well-characterized molecular landscape make them an ideal host for gene-editing applications aimed at dissecting oncogenic mechanisms.
EHMT2 (also known as G9a) encodes a histone methyltransferase that catalyzes mono- and dimethylation of lysine 9 on histone H3 (H3K9me1/2), a key repressive chromatin mark. This modification recruits heterochromatin protein 1 (HP1) and promotes transcriptional silencing. EHMT2 is regulated by upstream factors such as the transcription factor E2F1, MYC, and CDK1/cyclin B-mediated phosphorylation, which stabilizes the protein. It directly represses tumor suppressor genes, including CDKN1A (p21), CDH1 (E-cadherin), and PTEN, thereby driving cell cycle progression and proliferation. EHMT2 functions in multiprotein complexes with EHMT1 (GLP), WIZ, CTBP, and PCNA, and cooperates with other epigenetic modifiers like DNMT1 and PRC2 components.
In the A-549 lung adenocarcinoma background, which harbors KRAS mutations and active RAS signaling, EHMT2 is often overexpressed, contributing to the epigenetic silencing of growth-suppressive genes. Disruption of EHMT2 in this polyclonal population is expected to relieve H3K9me2-mediated repression at promoters of CDKN1A and other targets, potentially leading to cell cycle arrest and apoptosis. This makes the knockout cells a powerful tool for dissecting the interplay between oncogenic signaling and chromatin-mediated gene regulation in lung cancer.
This knockout product is ideal for a range of applications, including validating EHMT2 as a therapeutic target in lung adenocarcinoma, performing functional genomics screens, and testing the efficacy of EHMT2 inhibitors such as UNC0642 or BIX-01294. Representative assays include Western blotting to confirm EHMT2 loss, RT-qPCR and RNA-seq for transcriptomic changes, ChIP-qPCR to assess H3K9me2 levels at specific loci, and proliferation or apoptosis assays. For additional information or to inquire about this product, please contact Ascent Research.
